Cargando…
COVID-19 Therapeutic Options Under Investigation
Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatment...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424051/ https://www.ncbi.nlm.nih.gov/pubmed/32848795 http://dx.doi.org/10.3389/fphar.2020.01196 |
_version_ | 1783570256587915264 |
---|---|
author | Kaddoura, Malak AlIbrahim, Malak Hijazi, Ghina Soudani, Nadia Audi, Amani Alkalamouni, Habib Haddad, Salame Eid, Ali Zaraket, Hassan |
author_facet | Kaddoura, Malak AlIbrahim, Malak Hijazi, Ghina Soudani, Nadia Audi, Amani Alkalamouni, Habib Haddad, Salame Eid, Ali Zaraket, Hassan |
author_sort | Kaddoura, Malak |
collection | PubMed |
description | Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclinical and clinical studies of potential antiviral and immunomodulatory compounds and molecules to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19–associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients. |
format | Online Article Text |
id | pubmed-7424051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74240512020-08-25 COVID-19 Therapeutic Options Under Investigation Kaddoura, Malak AlIbrahim, Malak Hijazi, Ghina Soudani, Nadia Audi, Amani Alkalamouni, Habib Haddad, Salame Eid, Ali Zaraket, Hassan Front Pharmacol Pharmacology Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclinical and clinical studies of potential antiviral and immunomodulatory compounds and molecules to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19–associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients. Frontiers Media S.A. 2020-08-06 /pmc/articles/PMC7424051/ /pubmed/32848795 http://dx.doi.org/10.3389/fphar.2020.01196 Text en Copyright © 2020 Kaddoura, AlIbrahim, Hijazi, Soudani, Audi, Alkalamouni, Haddad, Eid and Zaraket http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Kaddoura, Malak AlIbrahim, Malak Hijazi, Ghina Soudani, Nadia Audi, Amani Alkalamouni, Habib Haddad, Salame Eid, Ali Zaraket, Hassan COVID-19 Therapeutic Options Under Investigation |
title | COVID-19 Therapeutic Options Under Investigation |
title_full | COVID-19 Therapeutic Options Under Investigation |
title_fullStr | COVID-19 Therapeutic Options Under Investigation |
title_full_unstemmed | COVID-19 Therapeutic Options Under Investigation |
title_short | COVID-19 Therapeutic Options Under Investigation |
title_sort | covid-19 therapeutic options under investigation |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424051/ https://www.ncbi.nlm.nih.gov/pubmed/32848795 http://dx.doi.org/10.3389/fphar.2020.01196 |
work_keys_str_mv | AT kaddouramalak covid19therapeuticoptionsunderinvestigation AT alibrahimmalak covid19therapeuticoptionsunderinvestigation AT hijazighina covid19therapeuticoptionsunderinvestigation AT soudaninadia covid19therapeuticoptionsunderinvestigation AT audiamani covid19therapeuticoptionsunderinvestigation AT alkalamounihabib covid19therapeuticoptionsunderinvestigation AT haddadsalame covid19therapeuticoptionsunderinvestigation AT eidali covid19therapeuticoptionsunderinvestigation AT zarakethassan covid19therapeuticoptionsunderinvestigation |